Cell Therapeutics, Inc.

Stephen J Klaus

J Peter Klein

Anil M Kumar

Baoqing Gong

Gail E Underiner

David J Porubek

Paul Woodson

John E Tulinsky

Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 ('IL-12') intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula:Each X, Y and Z are independently selected from a member of the group consisting of C(R), N, N(R) and S. Each R, Rand Ris substituted or unsubstituted and is independently selected from a member of the group consisting of hydrogen, halo, oxo, Calkyl, Chydroxyalkyl, Cthioalkyl, Calkylamino, Calkylaminoalkyl, Caminoalkyl, Caminoalkoxyalkenyl, Caminoalkoxyalkynyl, Cdiaminoalkyl, Ctriaminoalkyl, Ctetraaminoalkyl, Caminotrialkoxyamino, Calkylamido, Calkylamidoalkyl, Camidoalkyl, Cacetamidoalkyl, Calkenyl, Calkynyl, Calkoxyl, Calkoxyalkyl, and Cdialkoxyalkyl.

Therapeutic compounds for inhibiting interleukin-12 signals and method for using same

Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same

Hydroxyl-containing compounds

Method of inhibiting interleukin-12 signaling

Growing community of inventors

Seattle, WA, United States of America

Stephen J Klaus